Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023720862> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2023720862 endingPage "300" @default.
- W2023720862 startingPage "289" @default.
- W2023720862 abstract "A phase II multiinstitutional clinical trial was conducted to evaluate the safety and efficacy of the subcutaneous outpatient administration of recombinant human interleukin-2 and alpha-interferon in patients with progressive metastatic renal cell carcinoma. One hundred and forty-five patients were entered on this study between October 1989 and May 1991. Among 134 patients evaluable for treatment response, there were six complete (4.5%) and twenty partial (14.9%) responders, with an overall response rate of 19.4% (95% confidence interval, 13-26%). The median duration of complete remissions was 228 (range 51(+)-520+) days; the median duration of partial tumor regressions was calculated at 226 (range 112-473+) days. The overall median survival from start of therapy was 14.2 (range 1-23+) months. Fever, chills and general fatigue occurred in the majority of patients treated and were measured at grade II, III and IV in up to 55%, 24% and 3% of all evaluable patients, respectively. Three patients each developed grade III hypotension, dyspnea and diarrhea; two patients each had grade III and grade IV elevations of alkaline phosphatase; two and one patients respectively, exhibited grade III anemia and grade IV thrombocytopenia; two patients experienced severe cutaneous toxicity. The majority of patients received treatment in the outpatient setting. In summary, the outpatient use of subcutaneous interleukin-2 and alpha-interferon was effective in patients with advanced metastatic renal cell carcinoma; it was associated with less toxicity and thus, could improve the therapeutic index of interleukin-2 based biologic therapy when compared against high dose intravenous therapy." @default.
- W2023720862 created "2016-06-24" @default.
- W2023720862 creator A5018711955 @default.
- W2023720862 creator A5020577473 @default.
- W2023720862 creator A5021163344 @default.
- W2023720862 creator A5049106859 @default.
- W2023720862 creator A5049681646 @default.
- W2023720862 creator A5053608897 @default.
- W2023720862 creator A5066679073 @default.
- W2023720862 creator A5076192223 @default.
- W2023720862 date "1993-01-01" @default.
- W2023720862 modified "2023-10-14" @default.
- W2023720862 title "Subcutaneous Recombinant Interleukin-2 and<i>a</i>-Interferon in Patients with Advanced Renal Cell Carcinoma: Results of a Multicenter Phase II Study" @default.
- W2023720862 cites W1529386421 @default.
- W2023720862 cites W1862901090 @default.
- W2023720862 cites W1884121283 @default.
- W2023720862 cites W1904017285 @default.
- W2023720862 cites W1979343444 @default.
- W2023720862 cites W2053414650 @default.
- W2023720862 cites W2155221651 @default.
- W2023720862 cites W2326245275 @default.
- W2023720862 cites W2340256585 @default.
- W2023720862 cites W2412446889 @default.
- W2023720862 cites W4231601205 @default.
- W2023720862 doi "https://doi.org/10.1089/cbr.1993.8.289" @default.
- W2023720862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7804370" @default.
- W2023720862 hasPublicationYear "1993" @default.
- W2023720862 type Work @default.
- W2023720862 sameAs 2023720862 @default.
- W2023720862 citedByCount "11" @default.
- W2023720862 countsByYear W20237208622013 @default.
- W2023720862 countsByYear W20237208622014 @default.
- W2023720862 crossrefType "journal-article" @default.
- W2023720862 hasAuthorship W2023720862A5018711955 @default.
- W2023720862 hasAuthorship W2023720862A5020577473 @default.
- W2023720862 hasAuthorship W2023720862A5021163344 @default.
- W2023720862 hasAuthorship W2023720862A5049106859 @default.
- W2023720862 hasAuthorship W2023720862A5049681646 @default.
- W2023720862 hasAuthorship W2023720862A5053608897 @default.
- W2023720862 hasAuthorship W2023720862A5066679073 @default.
- W2023720862 hasAuthorship W2023720862A5076192223 @default.
- W2023720862 hasConcept C126322002 @default.
- W2023720862 hasConcept C141071460 @default.
- W2023720862 hasConcept C2777472916 @default.
- W2023720862 hasConcept C2778248108 @default.
- W2023720862 hasConcept C2778594517 @default.
- W2023720862 hasConcept C29730261 @default.
- W2023720862 hasConcept C3020110884 @default.
- W2023720862 hasConcept C31760486 @default.
- W2023720862 hasConcept C71924100 @default.
- W2023720862 hasConcept C90924648 @default.
- W2023720862 hasConceptScore W2023720862C126322002 @default.
- W2023720862 hasConceptScore W2023720862C141071460 @default.
- W2023720862 hasConceptScore W2023720862C2777472916 @default.
- W2023720862 hasConceptScore W2023720862C2778248108 @default.
- W2023720862 hasConceptScore W2023720862C2778594517 @default.
- W2023720862 hasConceptScore W2023720862C29730261 @default.
- W2023720862 hasConceptScore W2023720862C3020110884 @default.
- W2023720862 hasConceptScore W2023720862C31760486 @default.
- W2023720862 hasConceptScore W2023720862C71924100 @default.
- W2023720862 hasConceptScore W2023720862C90924648 @default.
- W2023720862 hasIssue "4" @default.
- W2023720862 hasLocation W20237208621 @default.
- W2023720862 hasLocation W20237208622 @default.
- W2023720862 hasOpenAccess W2023720862 @default.
- W2023720862 hasPrimaryLocation W20237208621 @default.
- W2023720862 hasRelatedWork W1586374228 @default.
- W2023720862 hasRelatedWork W2003938723 @default.
- W2023720862 hasRelatedWork W2047967234 @default.
- W2023720862 hasRelatedWork W2118496982 @default.
- W2023720862 hasRelatedWork W2364998975 @default.
- W2023720862 hasRelatedWork W2369162477 @default.
- W2023720862 hasRelatedWork W2439875401 @default.
- W2023720862 hasRelatedWork W2986892476 @default.
- W2023720862 hasRelatedWork W4238867864 @default.
- W2023720862 hasRelatedWork W2525756941 @default.
- W2023720862 hasVolume "8" @default.
- W2023720862 isParatext "false" @default.
- W2023720862 isRetracted "false" @default.
- W2023720862 magId "2023720862" @default.
- W2023720862 workType "article" @default.